Eltrombopag is an orally bioavailable, small-molecule TPO-receptor agonist that interacts 485 with the transmembrane domain of the human TPO-receptor and initiates signaling cascades that 486 induce proliferation and differentiation from bone marrow progenitor cells.
Treatment of Thrombocytopenia in Patients with Chronic ITP PROMACTA is indicated for the treatment of thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.
Treatment of Thrombocytopenia in Patients with Hepatitis C Infection PROMACTA is indicated for the treatment of thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy.
Treatment of Severe Aplastic Anemia PROMACTA is indicated for the treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy.
